{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:13:36Z","timestamp":1793812416298,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["2016YFC0904100"],"award-info":[{"award-number":["2016YFC0904100"]}]},{"name":"Science and Technology Innovation Action Plan of Shanghai Science and Technology Committee","award":["No.17441902200"],"award-info":[{"award-number":["No.17441902200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD72, a co-receptor of B cell receptor (BCR), has been reported to have both positive and negative effects on B cell functions in several immunological diseases. The B cell plays an important role in the pathogenesis of primary Sjogren\u2019s syndrome (pSS). However, whether CD72 is involved in the process remains unknown. This study aimed to observe the possible role of CD72 in the pathogenesis of pSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 60 cases who fulfilled the American-European Consensus Group (AECG) criteria for the diagnosis of pSS and 61 gender and age-matched healthy controls were recruited in this study. The percentage of CD72+ B cells was 85.31\u2009\u00b1\u20098.37% in pSS patients and 76.91\u2009\u00b1\u20098.50% in healthy controls(\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The percentage of CD72+ B cells was correlated to serum IgG levels in patients [\u03b2\u2009=\u20090.018(0.001\u20130.036),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034]. The level of serum soluble CD72 was significantly higher in pSS patients than the one in healthy controls (0.41 (0.29) vs 0.07 (0.08) ng\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The percentage of CD72+ B cells was upregulated in pSS patients and was correlated to the serum IgG level, which revealed the hyperactivity of B cells in this disease. The serum soluble CD72 level was also increased in pSS patients. These results indicated a potential role of CD72 in the pathogenesis of pSS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12865-020-00351-2","type":"journal-article","created":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T11:02:45Z","timestamp":1587294165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A regulatory role for CD72 expression on B cells and increased soluble CD72 in primary Sjogren\u2019s syndrome"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuqi","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,19]]},"reference":[{"key":"351_CR1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 2002;61:554\u20138.","journal-title":"Ann Rheum Dis"},{"key":"351_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","volume":"89","author":"SS Kassan","year":"1978","unstructured":"Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888\u201392.","journal-title":"Ann Intern Med"},{"key":"351_CR3","doi-asserted-by":"publisher","first-page":"e3821","DOI":"10.1136\/bmj.e3821","volume":"344","author":"M Ramos-Casals","year":"2012","unstructured":"Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X. Primary Sjogren syndrome. Br Med J. 2012;344:e3821. https:\/\/doi.org\/10.1136\/bmj.e3821.","journal-title":"Br Med J"},{"key":"351_CR4","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","volume":"74","author":"B Qin","year":"2014","unstructured":"Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. Epidemiology of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2014;74:1983\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205375.","journal-title":"Ann Rheum Dis"},{"key":"351_CR5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/rheumatology\/kep141","volume":"48","author":"JM Meijer","year":"2009","unstructured":"Meijer JM, Meiners PM, Huddleston Slater JJR, Spijkervet FKL, Kallenberg CGM, Vissink A, Bootsma H. Health-related quality of life, employment and disability in patients with Sjogren\u2019s syndrome. Rheumatology (Oxford). 2009;48:1077\u201382. https:\/\/doi.org\/10.1093\/rheumatology\/kep141.","journal-title":"Rheumatology (Oxford)"},{"key":"351_CR6","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar4359","volume":"15","author":"F Carubbi","year":"2013","unstructured":"Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, Pantano I, Liakouli V, Alvaro S, Alunno A, Manzo A, Ciccia F, Gerli R, Triolo G, Giacomelli R. Efficacy and safety of rituximab treatment in early primary Sjogren\u2019s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15:R172. https:\/\/doi.org\/10.1186\/ar4359.","journal-title":"Arthritis Res Ther"},{"key":"351_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10875-008-9264-6","volume":"29","author":"H-J Wu","year":"2009","unstructured":"Wu H-J, Bondada S. CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function. J Clin Immunol. 2009;29:12\u201321. https:\/\/doi.org\/10.1007\/s10875-008-9264-6.","journal-title":"J Clin Immunol"},{"key":"351_CR8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0960-9822(07)00421-6","volume":"8","author":"Y Wu","year":"1998","unstructured":"Wu Y, Nadler MJ, Brennan LA, Gish GD, Timms JF, Fusaki N, Jongstra-Bilen J, Tada N, Pawson T, Wither J, Neel BG, Hozumi N. The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol. 1998;8:1009\u201317.","journal-title":"Curr Biol"},{"key":"351_CR9","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.4049\/jimmunol.160.10.4662","volume":"160","author":"T Adachi","year":"1998","unstructured":"Adachi T, Flaswinkel H, Yakura H, Reth M, Tsubata T. The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol. 1998;160:4662\u20135.","journal-title":"J Immunol"},{"key":"351_CR10","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1326::AID-IMMU1326>3.0.CO;2-Q","volume":"30","author":"N Fusaki","year":"2000","unstructured":"Fusaki N, Tomita S, Wu Y, Okamoto N, Goitsuka R, Kitamura D, Hozumi N. BLNK is associated with the CD72\/SHP-1\/Grb2 complex in the WEHI231 cell line after membrane IgM cross-linking. Eur J Immunol. 2000;30:1326\u201330.","journal-title":"Eur J Immunol"},{"key":"351_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0952-7915(99)80042-9","volume":"11","author":"KS Campbell","year":"1999","unstructured":"Campbell KS. Signal transduction from the B cell antigen-receptor. Curr Opin Immunol. 1999;11:256\u201364.","journal-title":"Curr Opin Immunol"},{"key":"351_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1074-7613(00)00062-5","volume":"13","author":"A Kumanogoh","year":"2000","unstructured":"Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T, Matsumoto M, Yoshida K, Yakura H, Pan C, Parnes JR, Kikutani H. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity. 2000;13:621\u201331.","journal-title":"Immunity."},{"key":"351_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/intimm\/dxg098","volume":"15","author":"I Ishida","year":"2003","unstructured":"Ishida I, Kumanogoh A, Suzuki K, Akahani S, Noda K, Kikutani H. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int Immunol. 2003;15:1027\u201334.","journal-title":"Int Immunol"},{"key":"351_CR14","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4049\/jimmunol.137.6.1793","volume":"137","author":"EC Snow","year":"1986","unstructured":"Snow EC, Mond JJ, Subbarao B. Enhancement by monoclonal anti-Lyb-2 antibody of antigen-specific B lymphocyte expansion stimulated by TNP-Ficoll and T lymphocyte-derived factors. J Immunol. 1986;137:1793\u20136.","journal-title":"J Immunol"},{"key":"351_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1074-7613(00)80124-7","volume":"11","author":"C Pan","year":"1999","unstructured":"Pan C, Baumgarth N, Parnes JR. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity. 1999;11:495\u2013506.","journal-title":"Immunity."},{"key":"351_CR16","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.4049\/jimmunol.176.9.5321","volume":"176","author":"DH Li","year":"2006","unstructured":"Li DH, Tung JW, Tarner IH, Snow AL, Yukinari T, Ngernmaneepothong R, Martinez OM, Parnes JR. CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes. J Immunol. 2006;176:5321\u20138.","journal-title":"J Immunol"},{"key":"351_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/intimm\/8.6.867","volume":"8","author":"T Nomura","year":"1996","unstructured":"Nomura T, Han H, Howard MC, Yagita H, Yakura H, Honjo T, Tsubata T. Antigen receptor-mediated B cell death is blocked by signaling via CD72 or treatment with dextran sulfate and is defective in autoimmunity-prone mice. Int Immunol. 1996;8:867\u201375.","journal-title":"Int Immunol"},{"key":"351_CR18","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/eji.200425775","volume":"35","author":"T Baba","year":"2005","unstructured":"Baba T, Fusaki N, Aoyama A, Li DH, Okamura RM, Parnes JR, Hozumi N. Dual regulation of BCR-mediated growth inhibition signaling by CD72. Eur J Immunol. 2005;35:1634\u201342. https:\/\/doi.org\/10.1002\/eji.200425775.","journal-title":"Eur J Immunol"},{"key":"351_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1074-7613(00)00063-7","volume":"13","author":"W Shi","year":"2000","unstructured":"Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, Yukawa K, Ikawa M, Okabe M, Parnes JR, Yoshida K, Kikutani H. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity. 2000;13:633\u201342.","journal-title":"Immunity."},{"key":"351_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.semarthrit.2013.11.010","volume":"43","author":"Z Vadasz","year":"2014","unstructured":"Vadasz Z, Haj T, Balbir A, Peri R, Rosner I, Slobodin G, Kessel A, Toubi E. A regulatory role for CD72 expression on B cells in systemic lupus erythematosus. Semin Arthritis Rheum. 2014;43:767\u201371. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.11.010.","journal-title":"Semin Arthritis Rheum"},{"key":"351_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clim.2016.02.004","volume":"164","author":"Z Vadasz","year":"2016","unstructured":"Vadasz Z, Goldeberg Y, Halasz K, Rosner I, Valesini G, Conti F, Perricone C, Sthoeger Z, Bezalel SR, Tzioufas AG, Levin NA, Shoenfeld Y, Toubi E. Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis. Clin Immunol. 2016;164:114\u20138. https:\/\/doi.org\/10.1016\/j.clim.2016.02.004.","journal-title":"Clin Immunol"},{"key":"351_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10517-014-2533-x","volume":"157","author":"EM Kuklina","year":"2014","unstructured":"Kuklina EM, Baidina TV, Danchenko IY, Nekrasova IV. Semaforin Sema4D in the immune system in multiple sclerosis. Bull Exp Biol Med. 2014;157:234\u20137. https:\/\/doi.org\/10.1007\/s10517-014-2533-x.","journal-title":"Bull Exp Biol Med"},{"key":"351_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1134\/S001249661405007X","volume":"458","author":"EM Kuklina","year":"2014","unstructured":"Kuklina EM, Nekrasova IV, Baidina TV, Danchenko IY. The role of the sema4D\/CD72-dependent signal in the regulation of B-cell activity in multiple sclerosis. Dokl Biol Sci. 2014;458:316\u20138. https:\/\/doi.org\/10.1134\/S001249661405007X.","journal-title":"Dokl Biol Sci"},{"key":"351_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1399-0039.2004.00187.x","volume":"63","author":"AJF Smith","year":"2004","unstructured":"Smith AJF, Gordon TP, Macardle PJ. Increased expression of the B-cell-regulatory molecule CD72 in primary Sjogren\u2019s syndrome. Tissue Antigens. 2004;63:255\u20139. https:\/\/doi.org\/10.1111\/j.1399-0039.2004.00187.x.","journal-title":"Tissue Antigens"},{"key":"351_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/bjh.14671","volume":"178","author":"M Lyu","year":"2017","unstructured":"Lyu M, Hao Y, Li Y, Lyu C, Liu W, Li H, Xue F, Liu X, Yang R. Upregulation of CD72 expression on CD19 + CD27 + memory B cells by CD40L in primary immune thrombocytopenia. Br J Haematol. 2017;178:308\u201318. https:\/\/doi.org\/10.1111\/bjh.14671.","journal-title":"Br J Haematol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-020-00351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-020-00351-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-020-00351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T23:30:07Z","timestamp":1696030207000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-020-00351-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1186\/s12865-020-00351-2","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,19]]},"assertion":[{"value":"3 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ruijin Hospital Ethics Committee at the Shanghai Jiao Tong University School of Medicine (2010 No. 29) in agreement with the Declaration of Helsinki. All subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}